Goldman Sachs
EUCRW

Goldman Sachs’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Goldman Sachs’s Portfolio EUCRW Stock Details EUCRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25,033
Closed -$1.39K – 6378
2022
Q4 		$1.39K Sell
25,033
-134,400
-84% -$4.79K ﹤0.01% 5896
2022
Q3 		$4K Sell
159,433
-200
-0.1% -$13 ﹤0.01% 6120
2022
Q2 		$5K Sell
159,633
-6,400
-4% -$1.03K ﹤0.01% 6345
2022
Q1 		$31K Buy
+166,033
New +$67.3K ﹤0.01% 6349

Other funds holding EUCRW

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

Goldman Sachs's EUCRW Position: Q1 2023 in Review

Goldman Sachs sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q1 2023, closing a stake of 25,033 shares — an estimated $1.39K sold.

Goldman Sachs first reported a position in EUCRW in Q1 2022 and held it in 4 quarters. The position peaked at $31K in Q1 2022. 22 funds tracked by Wall St. Rank hold EUCRW as of Q1 2023.

  • Goldman Sachs reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q1 2023 after selling out during the quarter.
  • Goldman Sachs sold 25,033 Eucrates Biomedical Acquisition Corp. Warrant shares in Q1 2023, an estimated $1.39K.
  • Goldman Sachs first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2022 and held it in 4 quarters.
  • Goldman Sachs's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $31K in Q1 2022.
  • 22 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.